Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIATE Study
2025-521841-26-00Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of venetoclax in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Central Denmark Region. Primary endpoints: Primary safety endpoint and Primary effect endpoint. Planned start Jan 2026; status: authorised.
02
Drugs
venetoclax
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2025-521841-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521841-26-00.